TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis — Stella

Home/EGFR Inhibitor-associated Rash/

View on ClinicalTrials.gov

Recruiting

Back to EGFR Inhibitor-associated Rash trials

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(3 sites)

France

Hopital Privé Jean Mermoz, Lyon

Institut Paoli Calmette, Marseille

Centre Antoine Lacassagne, Nice

Key details

Phase

Safety & dosing

Sponsor

Tarian Pharma

Enrollment target

~60 participants

Started

January 2025

Primary completion

September 2026

Age range

18 Years – 80 Years

Last updated February 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.